 - Increased cardiac risk: symptomatic andor medication requiring congestive heart failure or clinically relevant valvular heart disease or unstable angor pectoris or myocardial infarction within 12 months before inclusion in the study, or grade 1 arrhythmia or any grade requiring treatment, or uncontrolled arterial hypertension 160100 mmHg despite optimal medical therapy. 